CapsoVision, Inc 8-K

What Happened

• CapsoVision announced an amendment (effective March 9, 2026; filed on Form 8-K March 13, 2026) to its development agreement with Canon Inc. for CMOS image sensor samples used in CapsoVision’s capsule endoscopies. The amendment increases the total development fee by $1.0 million to reflect increased feature specifications.

Key Details

• Original development fee was approximately $4.1 million (initial $1.0M paid on effectiveness + approximately $3.1M remaining upon delivery of specified sensors); the amendment increases the total fee by $1.0M.
• The remaining development fee will be adjusted accordingly and paid pursuant to the original Agreement’s Articles 12.4–12.6 by adding an agreed amount to the unit price of sensors purchased under a future master purchase agreement.
• The amendment states the Additional Amount defined in Section 12.5 remains unchanged and that all other terms of the original agreement remain in full force and effect.
• The amendment was filed as Exhibit 10.1 to the current Form 8-K.

Why It Matters

• This amendment increases CapsoVision’s committed development expense with Canon by $1.0M, which is material to the project funding and future unit pricing for the CMOS sensors. Because payment of the remaining fee is tied to unit purchases, the change also affects the economics of future sensor buys. Investors should note the company’s continued partnership with Canon aimed at obtaining FDA 510(k) clearance for capsules using Canon sensors, and that this agreement influences near‑term cash obligations and product cost structure.